Loading
A phase 2/3 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, terminated.
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS is a phase 2/3 interventional study registered as NCT03699475 by Bellicum Pharmaceuticals, with 1 participants enrolled, started 2018-12-27. Conditions recorded: Acute Myeloid Leukemia and Myelodysplastic Syndromes. Interventions recorded: rivogenlecleucel, rimiducid, Cyclophosphamide and haplo-HSCT.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/